nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—Epirubicin—urinary bladder cancer	0.254	0.519	CrCtD
Valrubicin—Doxorubicin—urinary bladder cancer	0.235	0.481	CrCtD
Valrubicin—TOP2A—Epirubicin—urinary bladder cancer	0.0733	0.433	CbGbCtD
Valrubicin—TOP2A—Etoposide—urinary bladder cancer	0.0571	0.337	CbGbCtD
Valrubicin—Daunorubicin—Epirubicin—urinary bladder cancer	0.0542	0.173	CrCrCtD
Valrubicin—Idarubicin—Epirubicin—urinary bladder cancer	0.0542	0.173	CrCrCtD
Valrubicin—Doxorubicin—Epirubicin—urinary bladder cancer	0.0542	0.173	CrCrCtD
Valrubicin—Idarubicin—Doxorubicin—urinary bladder cancer	0.0501	0.16	CrCrCtD
Valrubicin—Epirubicin—Doxorubicin—urinary bladder cancer	0.0501	0.16	CrCrCtD
Valrubicin—Daunorubicin—Doxorubicin—urinary bladder cancer	0.0501	0.16	CrCrCtD
Valrubicin—TOP2A—Doxorubicin—urinary bladder cancer	0.039	0.23	CbGbCtD
Valrubicin—Epirubicin—UGT2B7—urinary bladder cancer	0.000725	0.336	CrCbGaD
Valrubicin—Daunorubicin—POR—urinary bladder cancer	0.00063	0.292	CrCbGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.000539	0.097	CbGpPWpGaD
Valrubicin—Skin irritation—Fluorouracil—urinary bladder cancer	0.000513	0.0257	CcSEcCtD
Valrubicin—Doxorubicin—POR—urinary bladder cancer	0.000511	0.237	CrCbGaD
Valrubicin—Local reaction—Fluorouracil—urinary bladder cancer	0.000401	0.0201	CcSEcCtD
Valrubicin—Anorectal discomfort—Etoposide—urinary bladder cancer	0.000352	0.0177	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.000327	0.0588	CbGpPWpGaD
Valrubicin—Doxorubicin—NQO1—urinary bladder cancer	0.000294	0.136	CrCbGaD
Valrubicin—Rectal tenesmus—Epirubicin—urinary bladder cancer	0.00029	0.0145	CcSEcCtD
Valrubicin—TOP2A—G0 and Early G1—CCNE1—urinary bladder cancer	0.000272	0.049	CbGpPWpGaD
Valrubicin—Rectal tenesmus—Doxorubicin—urinary bladder cancer	0.000268	0.0135	CcSEcCtD
Valrubicin—Cystitis noninfective—Thiotepa—urinary bladder cancer	0.000262	0.0131	CcSEcCtD
Valrubicin—Ageusia—Cisplatin—urinary bladder cancer	0.00026	0.013	CcSEcCtD
Valrubicin—Cystitis—Thiotepa—urinary bladder cancer	0.000259	0.013	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.000257	0.0462	CbGpPWpGaD
Valrubicin—Blood urea increased—Thiotepa—urinary bladder cancer	0.000253	0.0127	CcSEcCtD
Valrubicin—Bladder pain—Thiotepa—urinary bladder cancer	0.000243	0.0122	CcSEcCtD
Valrubicin—Proctalgia—Epirubicin—urinary bladder cancer	0.00023	0.0116	CcSEcCtD
Valrubicin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000226	0.167	CbGdCrCtD
Valrubicin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000226	0.167	CbGdCrCtD
Valrubicin—Ill-defined disorder—Mitomycin—urinary bladder cancer	0.000216	0.0109	CcSEcCtD
Valrubicin—Anaemia—Mitomycin—urinary bladder cancer	0.000216	0.0108	CcSEcCtD
Valrubicin—Proctalgia—Doxorubicin—urinary bladder cancer	0.000213	0.0107	CcSEcCtD
Valrubicin—Blood urea increased—Gemcitabine—urinary bladder cancer	0.000213	0.0107	CcSEcCtD
Valrubicin—Malaise—Mitomycin—urinary bladder cancer	0.00021	0.0106	CcSEcCtD
Valrubicin—Body temperature increased—Carboplatin—urinary bladder cancer	0.000202	0.0101	CcSEcCtD
Valrubicin—Anorectal discomfort—Epirubicin—urinary bladder cancer	0.000198	0.00991	CcSEcCtD
Valrubicin—Discomfort—Mitomycin—urinary bladder cancer	0.000196	0.00984	CcSEcCtD
Valrubicin—Local reaction—Epirubicin—urinary bladder cancer	0.000195	0.00979	CcSEcCtD
Valrubicin—Urinary retention—Thiotepa—urinary bladder cancer	0.000185	0.00929	CcSEcCtD
Valrubicin—Anorectal discomfort—Doxorubicin—urinary bladder cancer	0.000183	0.00917	CcSEcCtD
Valrubicin—Local reaction—Doxorubicin—urinary bladder cancer	0.000181	0.00906	CcSEcCtD
Valrubicin—Pelvic pain—Epirubicin—urinary bladder cancer	0.000178	0.00891	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.00017	0.0306	CbGpPWpGaD
Valrubicin—Pelvic pain—Doxorubicin—urinary bladder cancer	0.000164	0.00824	CcSEcCtD
Valrubicin—Dysuria—Thiotepa—urinary bladder cancer	0.000157	0.0079	CcSEcCtD
Valrubicin—Feeling abnormal—Mitomycin—urinary bladder cancer	0.000157	0.00787	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000157	0.0282	CbGpPWpGaD
Valrubicin—Irritability—Fluorouracil—urinary bladder cancer	0.000154	0.00771	CcSEcCtD
Valrubicin—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.000152	0.00762	CcSEcCtD
Valrubicin—Pneumonia—Thiotepa—urinary bladder cancer	0.000151	0.00757	CcSEcCtD
Valrubicin—Body temperature increased—Mitomycin—urinary bladder cancer	0.00015	0.00755	CcSEcCtD
Valrubicin—Irritability—Cisplatin—urinary bladder cancer	0.000146	0.00731	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.000145	0.0261	CbGpPWpGaD
Valrubicin—Haematuria—Thiotepa—urinary bladder cancer	0.000143	0.00718	CcSEcCtD
Valrubicin—Asthenia—Mitomycin—urinary bladder cancer	0.000137	0.00685	CcSEcCtD
Valrubicin—Ageusia—Epirubicin—urinary bladder cancer	0.000133	0.00669	CcSEcCtD
Valrubicin—Diarrhoea—Mitomycin—urinary bladder cancer	0.00013	0.00653	CcSEcCtD
Valrubicin—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.000128	0.00641	CcSEcCtD
Valrubicin—Pneumonia—Gemcitabine—urinary bladder cancer	0.000127	0.00637	CcSEcCtD
Valrubicin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000127	0.0941	CbGdCrCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000126	0.0227	CbGpPWpGaD
Valrubicin—Dizziness—Mitomycin—urinary bladder cancer	0.000126	0.00631	CcSEcCtD
Valrubicin—Pneumonia—Fluorouracil—urinary bladder cancer	0.000125	0.00626	CcSEcCtD
Valrubicin—Ageusia—Doxorubicin—urinary bladder cancer	0.000123	0.00619	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—SMC1B—urinary bladder cancer	0.000123	0.0221	CbGpPWpGaD
Valrubicin—Vasodilation procedure—Epirubicin—urinary bladder cancer	0.000123	0.00617	CcSEcCtD
Valrubicin—Vasodilation—Epirubicin—urinary bladder cancer	0.000123	0.00617	CcSEcCtD
Valrubicin—Vomiting—Mitomycin—urinary bladder cancer	0.000121	0.00607	CcSEcCtD
Valrubicin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.000121	0.00605	CcSEcCtD
Valrubicin—Haematuria—Gemcitabine—urinary bladder cancer	0.00012	0.00604	CcSEcCtD
Valrubicin—Rash—Mitomycin—urinary bladder cancer	0.00012	0.00602	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.00012	0.0216	CbGpPWpGaD
Valrubicin—Dermatitis—Mitomycin—urinary bladder cancer	0.00012	0.00602	CcSEcCtD
Valrubicin—Headache—Mitomycin—urinary bladder cancer	0.000119	0.00598	CcSEcCtD
Valrubicin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000118	0.0872	CbGdCrCtD
Valrubicin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000118	0.0872	CbGdCrCtD
Valrubicin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000118	0.0872	CbGdCrCtD
Valrubicin—Nocturia—Epirubicin—urinary bladder cancer	0.000116	0.00584	CcSEcCtD
Valrubicin—Vasodilation procedure—Doxorubicin—urinary bladder cancer	0.000114	0.00571	CcSEcCtD
Valrubicin—Vasodilation—Doxorubicin—urinary bladder cancer	0.000114	0.00571	CcSEcCtD
Valrubicin—Back pain—Thiotepa—urinary bladder cancer	0.000113	0.00569	CcSEcCtD
Valrubicin—Nausea—Mitomycin—urinary bladder cancer	0.000113	0.00567	CcSEcCtD
Valrubicin—Cystitis noninfective—Methotrexate—urinary bladder cancer	0.000113	0.00566	CcSEcCtD
Valrubicin—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000112	0.0056	CcSEcCtD
Valrubicin—Cystitis—Methotrexate—urinary bladder cancer	0.000111	0.00559	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00011	0.0198	CbGpPWpGaD
Valrubicin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0807	CbGdCrCtD
Valrubicin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0807	CbGdCrCtD
Valrubicin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0807	CbGdCrCtD
Valrubicin—Pneumonia—Etoposide—urinary bladder cancer	0.000108	0.00544	CcSEcCtD
Valrubicin—Anaemia—Thiotepa—urinary bladder cancer	0.000108	0.00544	CcSEcCtD
Valrubicin—Nocturia—Doxorubicin—urinary bladder cancer	0.000108	0.00541	CcSEcCtD
Valrubicin—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000106	0.00529	CcSEcCtD
Valrubicin—Bladder pain—Methotrexate—urinary bladder cancer	0.000104	0.00524	CcSEcCtD
Valrubicin—Cystitis—Epirubicin—urinary bladder cancer	0.000104	0.00523	CcSEcCtD
Valrubicin—Blood urea increased—Epirubicin—urinary bladder cancer	0.000102	0.00512	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.0001	0.0181	CbGpPWpGaD
Valrubicin—Myalgia—Thiotepa—urinary bladder cancer	9.98e-05	0.00501	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	9.86e-05	0.0177	CbGpPWpGaD
Valrubicin—Bladder pain—Epirubicin—urinary bladder cancer	9.77e-05	0.0049	CcSEcCtD
Valrubicin—Cystitis noninfective—Doxorubicin—urinary bladder cancer	9.76e-05	0.0049	CcSEcCtD
Valrubicin—Cystitis—Doxorubicin—urinary bladder cancer	9.65e-05	0.00484	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	9.62e-05	0.0173	CbGpPWpGaD
Valrubicin—Back pain—Gemcitabine—urinary bladder cancer	9.54e-05	0.00479	CcSEcCtD
Valrubicin—Blood urea increased—Doxorubicin—urinary bladder cancer	9.44e-05	0.00473	CcSEcCtD
Valrubicin—Ill-defined disorder—Gemcitabine—urinary bladder cancer	9.15e-05	0.00459	CcSEcCtD
Valrubicin—Anaemia—Gemcitabine—urinary bladder cancer	9.12e-05	0.00457	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	9.09e-05	0.0164	CbGpPWpGaD
Valrubicin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	9.09e-05	0.0674	CbGdCrCtD
Valrubicin—Flatulence—Cisplatin—urinary bladder cancer	9.06e-05	0.00455	CcSEcCtD
Valrubicin—Bladder pain—Doxorubicin—urinary bladder cancer	9.04e-05	0.00453	CcSEcCtD
Valrubicin—Anaemia—Fluorouracil—urinary bladder cancer	8.96e-05	0.0045	CcSEcCtD
Valrubicin—Malaise—Gemcitabine—urinary bladder cancer	8.9e-05	0.00446	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	8.9e-05	0.016	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	8.72e-05	0.00438	CcSEcCtD
Valrubicin—Ill-defined disorder—Cisplatin—urinary bladder cancer	8.53e-05	0.00428	CcSEcCtD
Valrubicin—Anaemia—Cisplatin—urinary bladder cancer	8.5e-05	0.00426	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	8.41e-05	0.0151	CbGpPWpGaD
Valrubicin—Myalgia—Gemcitabine—urinary bladder cancer	8.4e-05	0.00421	CcSEcCtD
Valrubicin—Chest pain—Gemcitabine—urinary bladder cancer	8.4e-05	0.00421	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	8.36e-05	0.015	CbGpPWpGaD
Valrubicin—Discomfort—Gemcitabine—urinary bladder cancer	8.3e-05	0.00416	CcSEcCtD
Valrubicin—Malaise—Cisplatin—urinary bladder cancer	8.29e-05	0.00416	CcSEcCtD
Valrubicin—Chest pain—Fluorouracil—urinary bladder cancer	8.26e-05	0.00414	CcSEcCtD
Valrubicin—Myalgia—Fluorouracil—urinary bladder cancer	8.26e-05	0.00414	CcSEcCtD
Valrubicin—Discomfort—Fluorouracil—urinary bladder cancer	8.16e-05	0.00409	CcSEcCtD
Valrubicin—Back pain—Etoposide—urinary bladder cancer	8.15e-05	0.00409	CcSEcCtD
Valrubicin—Irritability—Methotrexate—urinary bladder cancer	8e-05	0.00401	CcSEcCtD
Valrubicin—Feeling abnormal—Thiotepa—urinary bladder cancer	7.89e-05	0.00396	CcSEcCtD
Valrubicin—Myalgia—Cisplatin—urinary bladder cancer	7.83e-05	0.00393	CcSEcCtD
Valrubicin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	7.83e-05	0.00393	CcSEcCtD
Valrubicin—Ill-defined disorder—Etoposide—urinary bladder cancer	7.82e-05	0.00392	CcSEcCtD
Valrubicin—Anaemia—Etoposide—urinary bladder cancer	7.79e-05	0.00391	CcSEcCtD
Valrubicin—Discomfort—Cisplatin—urinary bladder cancer	7.73e-05	0.00388	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	7.69e-05	0.0138	CbGpPWpGaD
Valrubicin—Malaise—Etoposide—urinary bladder cancer	7.6e-05	0.00381	CcSEcCtD
Valrubicin—Body temperature increased—Thiotepa—urinary bladder cancer	7.57e-05	0.0038	CcSEcCtD
Valrubicin—Abdominal pain—Thiotepa—urinary bladder cancer	7.57e-05	0.0038	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	7.47e-05	0.0134	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	7.33e-05	0.00368	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	7.21e-05	0.00362	CcSEcCtD
Valrubicin—Chest pain—Etoposide—urinary bladder cancer	7.17e-05	0.0036	CcSEcCtD
Valrubicin—Discomfort—Etoposide—urinary bladder cancer	7.09e-05	0.00356	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	7.07e-05	0.0127	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	7.05e-05	0.0127	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	6.94e-05	0.0125	CbGpPWpGaD
Valrubicin—Asthenia—Thiotepa—urinary bladder cancer	6.87e-05	0.00345	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	6.84e-05	0.00343	CcSEcCtD
Valrubicin—Dysuria—Methotrexate—urinary bladder cancer	6.77e-05	0.0034	CcSEcCtD
Valrubicin—Pruritus—Thiotepa—urinary bladder cancer	6.77e-05	0.0034	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.73e-05	0.0121	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	6.69e-05	0.012	CbGpPWpGaD
Valrubicin—Feeling abnormal—Gemcitabine—urinary bladder cancer	6.63e-05	0.00333	CcSEcCtD
Valrubicin—Diarrhoea—Thiotepa—urinary bladder cancer	6.55e-05	0.00329	CcSEcCtD
Valrubicin—Feeling abnormal—Fluorouracil—urinary bladder cancer	6.52e-05	0.00327	CcSEcCtD
Valrubicin—Pneumonia—Methotrexate—urinary bladder cancer	6.49e-05	0.00326	CcSEcCtD
Valrubicin—Body temperature increased—Gemcitabine—urinary bladder cancer	6.36e-05	0.00319	CcSEcCtD
Valrubicin—Dysuria—Epirubicin—urinary bladder cancer	6.34e-05	0.00318	CcSEcCtD
Valrubicin—Dizziness—Thiotepa—urinary bladder cancer	6.33e-05	0.00318	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	6.3e-05	0.0113	CbGpPWpGaD
Valrubicin—Pollakiuria—Epirubicin—urinary bladder cancer	6.26e-05	0.00314	CcSEcCtD
Valrubicin—Body temperature increased—Fluorouracil—urinary bladder cancer	6.26e-05	0.00314	CcSEcCtD
Valrubicin—Feeling abnormal—Cisplatin—urinary bladder cancer	6.18e-05	0.0031	CcSEcCtD
Valrubicin—Haematuria—Methotrexate—urinary bladder cancer	6.16e-05	0.00309	CcSEcCtD
Valrubicin—Hyperglycaemia—Epirubicin—urinary bladder cancer	6.11e-05	0.00307	CcSEcCtD
Valrubicin—Vomiting—Thiotepa—urinary bladder cancer	6.09e-05	0.00305	CcSEcCtD
Valrubicin—Pneumonia—Epirubicin—urinary bladder cancer	6.08e-05	0.00305	CcSEcCtD
Valrubicin—Rash—Thiotepa—urinary bladder cancer	6.03e-05	0.00303	CcSEcCtD
Valrubicin—Dermatitis—Thiotepa—urinary bladder cancer	6.03e-05	0.00303	CcSEcCtD
Valrubicin—Headache—Thiotepa—urinary bladder cancer	6e-05	0.00301	CcSEcCtD
Valrubicin—Body temperature increased—Cisplatin—urinary bladder cancer	5.93e-05	0.00298	CcSEcCtD
Valrubicin—Urinary tract infection—Epirubicin—urinary bladder cancer	5.87e-05	0.00295	CcSEcCtD
Valrubicin—Dysuria—Doxorubicin—urinary bladder cancer	5.86e-05	0.00294	CcSEcCtD
Valrubicin—Pollakiuria—Doxorubicin—urinary bladder cancer	5.79e-05	0.00291	CcSEcCtD
Valrubicin—Asthenia—Gemcitabine—urinary bladder cancer	5.78e-05	0.0029	CcSEcCtD
Valrubicin—Haematuria—Epirubicin—urinary bladder cancer	5.76e-05	0.00289	CcSEcCtD
Valrubicin—Pruritus—Gemcitabine—urinary bladder cancer	5.7e-05	0.00286	CcSEcCtD
Valrubicin—Nausea—Thiotepa—urinary bladder cancer	5.68e-05	0.00285	CcSEcCtD
Valrubicin—Feeling abnormal—Etoposide—urinary bladder cancer	5.67e-05	0.00284	CcSEcCtD
Valrubicin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	5.66e-05	0.00284	CcSEcCtD
Valrubicin—Pneumonia—Doxorubicin—urinary bladder cancer	5.62e-05	0.00282	CcSEcCtD
Valrubicin—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.62e-05	0.00282	CcSEcCtD
Valrubicin—Pruritus—Fluorouracil—urinary bladder cancer	5.6e-05	0.00281	CcSEcCtD
Valrubicin—Diarrhoea—Gemcitabine—urinary bladder cancer	5.51e-05	0.00276	CcSEcCtD
Valrubicin—Abdominal pain—Etoposide—urinary bladder cancer	5.43e-05	0.00273	CcSEcCtD
Valrubicin—Body temperature increased—Etoposide—urinary bladder cancer	5.43e-05	0.00273	CcSEcCtD
Valrubicin—Urinary tract infection—Doxorubicin—urinary bladder cancer	5.43e-05	0.00273	CcSEcCtD
Valrubicin—Diarrhoea—Fluorouracil—urinary bladder cancer	5.42e-05	0.00272	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	5.41e-05	0.00973	CbGpPWpGaD
Valrubicin—Asthenia—Cisplatin—urinary bladder cancer	5.38e-05	0.0027	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.35e-05	0.00963	CbGpPWpGaD
Valrubicin—Oedema peripheral—Epirubicin—urinary bladder cancer	5.34e-05	0.00268	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	5.34e-05	0.0096	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	5.34e-05	0.0096	CbGpPWpGaD
Valrubicin—Haematuria—Doxorubicin—urinary bladder cancer	5.33e-05	0.00267	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.26e-05	0.00946	CbGpPWpGaD
Valrubicin—Dizziness—Fluorouracil—urinary bladder cancer	5.23e-05	0.00263	CcSEcCtD
Valrubicin—Diarrhoea—Cisplatin—urinary bladder cancer	5.13e-05	0.00258	CcSEcCtD
Valrubicin—Vomiting—Gemcitabine—urinary bladder cancer	5.12e-05	0.00257	CcSEcCtD
Valrubicin—Rash—Gemcitabine—urinary bladder cancer	5.08e-05	0.00255	CcSEcCtD
Valrubicin—Dermatitis—Gemcitabine—urinary bladder cancer	5.07e-05	0.00254	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	5.05e-05	0.00908	CbGpPWpGaD
Valrubicin—Headache—Gemcitabine—urinary bladder cancer	5.04e-05	0.00253	CcSEcCtD
Valrubicin—Vomiting—Fluorouracil—urinary bladder cancer	5.03e-05	0.00253	CcSEcCtD
Valrubicin—Rash—Fluorouracil—urinary bladder cancer	4.99e-05	0.0025	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	4.99e-05	0.00897	CbGpPWpGaD
Valrubicin—Dermatitis—Fluorouracil—urinary bladder cancer	4.99e-05	0.0025	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	4.97e-05	0.00893	CbGpPWpGaD
Valrubicin—Headache—Fluorouracil—urinary bladder cancer	4.96e-05	0.00249	CcSEcCtD
Valrubicin—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.94e-05	0.00248	CcSEcCtD
Valrubicin—Asthenia—Etoposide—urinary bladder cancer	4.93e-05	0.00247	CcSEcCtD
Valrubicin—Back pain—Methotrexate—urinary bladder cancer	4.88e-05	0.00245	CcSEcCtD
Valrubicin—Pruritus—Etoposide—urinary bladder cancer	4.86e-05	0.00244	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	4.8e-05	0.00864	CbGpPWpGaD
Valrubicin—Nausea—Gemcitabine—urinary bladder cancer	4.78e-05	0.0024	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	4.77e-05	0.00859	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	4.77e-05	0.00859	CbGpPWpGaD
Valrubicin—Vomiting—Cisplatin—urinary bladder cancer	4.77e-05	0.00239	CcSEcCtD
Valrubicin—Rash—Cisplatin—urinary bladder cancer	4.73e-05	0.00237	CcSEcCtD
Valrubicin—Dermatitis—Cisplatin—urinary bladder cancer	4.73e-05	0.00237	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	4.71e-05	0.00846	CbGpPWpGaD
Valrubicin—Diarrhoea—Etoposide—urinary bladder cancer	4.7e-05	0.00236	CcSEcCtD
Valrubicin—Nausea—Fluorouracil—urinary bladder cancer	4.7e-05	0.00236	CcSEcCtD
Valrubicin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.68e-05	0.00235	CcSEcCtD
Valrubicin—Anaemia—Methotrexate—urinary bladder cancer	4.66e-05	0.00234	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.66e-05	0.00838	CbGpPWpGaD
Valrubicin—Flatulence—Epirubicin—urinary bladder cancer	4.65e-05	0.00233	CcSEcCtD
Valrubicin—Back pain—Epirubicin—urinary bladder cancer	4.57e-05	0.00229	CcSEcCtD
Valrubicin—Malaise—Methotrexate—urinary bladder cancer	4.55e-05	0.00228	CcSEcCtD
Valrubicin—Dizziness—Etoposide—urinary bladder cancer	4.55e-05	0.00228	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	4.47e-05	0.00804	CbGpPWpGaD
Valrubicin—Nausea—Cisplatin—urinary bladder cancer	4.46e-05	0.00224	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	4.4e-05	0.00791	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.38e-05	0.0022	CcSEcCtD
Valrubicin—Vomiting—Etoposide—urinary bladder cancer	4.37e-05	0.00219	CcSEcCtD
Valrubicin—Anaemia—Epirubicin—urinary bladder cancer	4.36e-05	0.00219	CcSEcCtD
Valrubicin—Rash—Etoposide—urinary bladder cancer	4.33e-05	0.00217	CcSEcCtD
Valrubicin—Dermatitis—Etoposide—urinary bladder cancer	4.33e-05	0.00217	CcSEcCtD
Valrubicin—Headache—Etoposide—urinary bladder cancer	4.31e-05	0.00216	CcSEcCtD
Valrubicin—Flatulence—Doxorubicin—urinary bladder cancer	4.31e-05	0.00216	CcSEcCtD
Valrubicin—Chest pain—Methotrexate—urinary bladder cancer	4.3e-05	0.00216	CcSEcCtD
Valrubicin—Myalgia—Methotrexate—urinary bladder cancer	4.3e-05	0.00216	CcSEcCtD
Valrubicin—Malaise—Epirubicin—urinary bladder cancer	4.26e-05	0.00214	CcSEcCtD
Valrubicin—Discomfort—Methotrexate—urinary bladder cancer	4.24e-05	0.00213	CcSEcCtD
Valrubicin—Back pain—Doxorubicin—urinary bladder cancer	4.23e-05	0.00212	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	4.14e-05	0.00744	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.12e-05	0.0074	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.1e-05	0.00737	CbGpPWpGaD
Valrubicin—Nausea—Etoposide—urinary bladder cancer	4.08e-05	0.00205	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.08e-05	0.00734	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.05e-05	0.00203	CcSEcCtD
Valrubicin—Anaemia—Doxorubicin—urinary bladder cancer	4.04e-05	0.00203	CcSEcCtD
Valrubicin—Myalgia—Epirubicin—urinary bladder cancer	4.02e-05	0.00202	CcSEcCtD
Valrubicin—Chest pain—Epirubicin—urinary bladder cancer	4.02e-05	0.00202	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	3.98e-05	0.00716	CbGpPWpGaD
Valrubicin—Discomfort—Epirubicin—urinary bladder cancer	3.97e-05	0.00199	CcSEcCtD
Valrubicin—Malaise—Doxorubicin—urinary bladder cancer	3.94e-05	0.00198	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	3.94e-05	0.00708	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	3.93e-05	0.00707	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.75e-05	0.00188	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	3.74e-05	0.00672	CbGpPWpGaD
Valrubicin—Chest pain—Doxorubicin—urinary bladder cancer	3.72e-05	0.00187	CcSEcCtD
Valrubicin—Myalgia—Doxorubicin—urinary bladder cancer	3.72e-05	0.00187	CcSEcCtD
Valrubicin—Discomfort—Doxorubicin—urinary bladder cancer	3.67e-05	0.00184	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.58e-05	0.00643	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	3.58e-05	0.00643	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.53e-05	0.00635	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.51e-05	0.00176	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	3.49e-05	0.00628	CbGpPWpGaD
Valrubicin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.39e-05	0.0017	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	3.38e-05	0.00608	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.37e-05	0.00169	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	3.34e-05	0.00601	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.27e-05	0.00588	CbGpPWpGaD
Valrubicin—Body temperature increased—Methotrexate—urinary bladder cancer	3.26e-05	0.00163	CcSEcCtD
Valrubicin—Abdominal pain—Methotrexate—urinary bladder cancer	3.26e-05	0.00163	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.25e-05	0.00163	CcSEcCtD
Valrubicin—Feeling abnormal—Epirubicin—urinary bladder cancer	3.18e-05	0.00159	CcSEcCtD
Valrubicin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.15e-05	0.00158	CcSEcCtD
Valrubicin—Abdominal pain—Epirubicin—urinary bladder cancer	3.05e-05	0.00153	CcSEcCtD
Valrubicin—Body temperature increased—Epirubicin—urinary bladder cancer	3.05e-05	0.00153	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3e-05	0.00539	CbGpPWpGaD
Valrubicin—Asthenia—Methotrexate—urinary bladder cancer	2.95e-05	0.00148	CcSEcCtD
Valrubicin—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.94e-05	0.00147	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.93e-05	0.00527	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.92e-05	0.00146	CcSEcCtD
Valrubicin—Pruritus—Methotrexate—urinary bladder cancer	2.91e-05	0.00146	CcSEcCtD
Valrubicin—Abdominal pain—Doxorubicin—urinary bladder cancer	2.82e-05	0.00141	CcSEcCtD
Valrubicin—Body temperature increased—Doxorubicin—urinary bladder cancer	2.82e-05	0.00141	CcSEcCtD
Valrubicin—Diarrhoea—Methotrexate—urinary bladder cancer	2.82e-05	0.00141	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	2.8e-05	0.00504	CbGpPWpGaD
Valrubicin—Asthenia—Epirubicin—urinary bladder cancer	2.76e-05	0.00139	CcSEcCtD
Valrubicin—Pruritus—Epirubicin—urinary bladder cancer	2.73e-05	0.00137	CcSEcCtD
Valrubicin—Dizziness—Methotrexate—urinary bladder cancer	2.72e-05	0.00137	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.65e-05	0.00476	CbGpPWpGaD
Valrubicin—Diarrhoea—Epirubicin—urinary bladder cancer	2.64e-05	0.00132	CcSEcCtD
Valrubicin—Vomiting—Methotrexate—urinary bladder cancer	2.62e-05	0.00131	CcSEcCtD
Valrubicin—Rash—Methotrexate—urinary bladder cancer	2.6e-05	0.0013	CcSEcCtD
Valrubicin—Dermatitis—Methotrexate—urinary bladder cancer	2.59e-05	0.0013	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	2.59e-05	0.00466	CbGpPWpGaD
Valrubicin—Headache—Methotrexate—urinary bladder cancer	2.58e-05	0.00129	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.56e-05	0.00461	CbGpPWpGaD
Valrubicin—Asthenia—Doxorubicin—urinary bladder cancer	2.56e-05	0.00128	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.56e-05	0.0046	CbGpPWpGaD
Valrubicin—Dizziness—Epirubicin—urinary bladder cancer	2.55e-05	0.00128	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2.55e-05	0.00458	CbGpPWpGaD
Valrubicin—Pruritus—Doxorubicin—urinary bladder cancer	2.52e-05	0.00127	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	2.45e-05	0.00441	CbGpPWpGaD
Valrubicin—Vomiting—Epirubicin—urinary bladder cancer	2.45e-05	0.00123	CcSEcCtD
Valrubicin—Nausea—Methotrexate—urinary bladder cancer	2.45e-05	0.00123	CcSEcCtD
Valrubicin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.44e-05	0.00122	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.44e-05	0.00438	CbGpPWpGaD
Valrubicin—Rash—Epirubicin—urinary bladder cancer	2.43e-05	0.00122	CcSEcCtD
Valrubicin—Dermatitis—Epirubicin—urinary bladder cancer	2.43e-05	0.00122	CcSEcCtD
Valrubicin—Headache—Epirubicin—urinary bladder cancer	2.41e-05	0.00121	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.37e-05	0.00426	CbGpPWpGaD
Valrubicin—Dizziness—Doxorubicin—urinary bladder cancer	2.36e-05	0.00118	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	2.34e-05	0.00421	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	2.32e-05	0.00417	CbGpPWpGaD
Valrubicin—Nausea—Epirubicin—urinary bladder cancer	2.29e-05	0.00115	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	2.28e-05	0.00409	CbGpPWpGaD
Valrubicin—Vomiting—Doxorubicin—urinary bladder cancer	2.27e-05	0.00114	CcSEcCtD
Valrubicin—Rash—Doxorubicin—urinary bladder cancer	2.25e-05	0.00113	CcSEcCtD
Valrubicin—Dermatitis—Doxorubicin—urinary bladder cancer	2.25e-05	0.00113	CcSEcCtD
Valrubicin—Headache—Doxorubicin—urinary bladder cancer	2.23e-05	0.00112	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.12e-05	0.00382	CbGpPWpGaD
Valrubicin—Nausea—Doxorubicin—urinary bladder cancer	2.12e-05	0.00106	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.08e-05	0.00374	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.98e-05	0.00357	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	1.98e-05	0.00357	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.98e-05	0.00356	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.96e-05	0.00353	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	1.78e-05	0.0032	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	1.77e-05	0.00319	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.74e-05	0.00314	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.73e-05	0.0031	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	1.67e-05	0.00301	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	1.54e-05	0.00277	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.52e-05	0.00273	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	1.36e-05	0.00244	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.28e-05	0.0023	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.24e-05	0.00223	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.18e-05	0.00212	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	1.15e-05	0.00206	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	1.11e-05	0.00199	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	1.05e-05	0.0019	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.03e-05	0.00185	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	9.19e-06	0.00165	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	7.55e-06	0.00136	CbGpPWpGaD
